FDA clears Bracco’s new ultrasound contrast delivery system for cardiovascular imaging
Bracco Imaging has secured U.S. Food and Drug Administration (FDA) clearance for VueJect, a new ultrasound contrast delivery system built specifically for cardiovascular imaging procedures. This represents the latest addition to Bracco’s contrast-enhanced ultrasound (CEUS) portfolio.
According to Bracco, VueJect was designed to improve workflow efficiency, provide consistency from one operator to the next and enable the continuous administration of ultrasound contrast agents such as Bracco’s Lumason.
The new delivery system also received authorization from Health Canada.
“VueJect is a defining addition to our CEUS ecosystem, adding a dedicated injector to our ultrasound-enhancing agent portfolio that is able to administer Lumason/SonoVue in dilution in echocardiography procedures,” Luca Frazzoli, global head of ultrasound with Bracco Imaging, said in a statement. “As we bring this technology to more markets, we expect it to change what sonographers and physicians come to expect from contrast administration, setting a new standard for consistency and confidence in everyday practice.”
“FDA clearance and Health Canada authorization mark an important milestone for clinicians across North America," added Robert Mitchell, MBA, Bracco’s director of ultrasound platforms in the America. “VueJect provides cardiac sonographers with a more standardized approach to contrast administration, helping deliver more consistent CEUS examinations, day in and day out.”
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.